Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coversin for eculizumab-resistant paroxysmal nocturnal hemoglobinuria
NL-OMON42383Phase 2Active, not recruiting
- Sponsor
- Akari Therapeutics
- Start
- Jan 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nomacopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Akari Therapeutics. Primary endpoint: Reduction in mean serum LDH from Day 0 to Day 28. Started Jan 2016; status: active, not recruiting.
02
Drugs
nomacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NL-OMON42383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42383.